233 related articles for article (PubMed ID: 35444116)
21. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
Chen X; Zhang J; Jiang Q; Yan F
J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
[TBL] [Abstract][Full Text] [Related]
22. Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.
Silva RB; Yap C; Carvajal R; Lee SM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250415
[TBL] [Abstract][Full Text] [Related]
23. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
Bayar MA; Ivanova A; Le Teuff G
Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
[TBL] [Abstract][Full Text] [Related]
24. Hybrid continuous reassessment method with overdose control for safer dose escalation.
Ghosh D; Xie H; Zhang L; Chen F; Mohanty S; Li X
J Biopharm Stat; 2023 Sep; 33(5):586-595. PubMed ID: 36715485
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
Cunanan K; Koopmeiners JS
BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
[TBL] [Abstract][Full Text] [Related]
26. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
Takeda K; Yamaguchi Y; Taguri M; Morita S
Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
[TBL] [Abstract][Full Text] [Related]
27. Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics.
Gerard E; Zohar S; Thai HT; Lorenzato C; Riviere MK; Ursino M
Biometrics; 2022 Mar; 78(1):300-312. PubMed ID: 33527351
[TBL] [Abstract][Full Text] [Related]
28. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
Rossoni C; Bardet A; Geoerger B; Paoletti X
Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
[TBL] [Abstract][Full Text] [Related]
29. Small-sample behavior of novel phase I cancer trial designs.
Oron AP; Hoff PD
Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
[TBL] [Abstract][Full Text] [Related]
30. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
31. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
Zhang L; Yuan Y
Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
[TBL] [Abstract][Full Text] [Related]
32. dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.
Toumazi A; Comets E; Alberti C; Friede T; Lentz F; Stallard N; Zohar S; Ursino M
Comput Methods Programs Biomed; 2018 Apr; 157():163-177. PubMed ID: 29477425
[TBL] [Abstract][Full Text] [Related]
33. Comparison of design methods for a safety run-in phase of a phase II clinical trial.
Ji L; Alonzo TA
Clin Trials; 2023 Apr; 20(2):181-191. PubMed ID: 36628921
[TBL] [Abstract][Full Text] [Related]
34. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
[TBL] [Abstract][Full Text] [Related]
35. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling.
Su X; Li Y; Müller P; Hsu CW; Pan H; Do KA
Pharm Stat; 2022 Nov; 21(6):1149-1166. PubMed ID: 35748220
[TBL] [Abstract][Full Text] [Related]
36. A 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development.
Zhang P; Li XN; Lu K; Wu C
Contemp Clin Trials; 2022 Nov; 122():106931. PubMed ID: 36174958
[TBL] [Abstract][Full Text] [Related]
37. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
38. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
[TBL] [Abstract][Full Text] [Related]
39. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
[TBL] [Abstract][Full Text] [Related]
40. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
